With autism spectrum disorder (ASD) affecting between 1-2% of the population and affecting all racial, ethnic, and socioeconomic groups, the condition is becoming of global importance. While the pharma industry has not yet been able to deliver a solution for this disease, the cell therapy industry is now undertaking the challenge. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Dr. Joseph Purita receives prestigious AAOSCP award for noteworthy contributions to stem cell science and medicine.
The American Academy of Stem Cell Physicians (AAOSCP) is honored to announce that Dr. Joseph Purita, a pioneer in the use of Stem Cell and PRP therapy for orthopedic conditions, has been awarded the prestigious “Stem Cell Scientist Physician Award.” Dr. Purita received this honor at the AAOSCP’s recent Scientific Congress and Workshop at the Mandarin Oriental in Miami, Florida, held over May 3-5, 2019. The event featured 40+ world-class speakers, integrated the use of live patients, and included three days of interactive workshops with small participant-to-instructor ratios. [Read more…]
FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]
MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]
Talaris Therapeutics’ RMAT and Promising Phase 2 Data of Cell Therapy for Living Donor Kidney Transplant Recipients
BOSTON & LOUISVILLE, Ky.–Apr 18, 2019–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results of its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) recipients. The therapy’s strong durability of benefit and safety profile support the initiation of a Phase 3 clinical trial in LDKT later this year.